The ATLAS System’s acceptance into the U.S. FDA TAP Pilot Program follows its 2024 Breakthrough Device Designation, placing Optheras among a limited number of companies to receive both recognitions. Participation in the TAP Program establishes structured, ongoing engagement with the FDA through the device’s regulatory development and review process Optheras A/S, a medical device company … Continue reading Optheras’ ATLAS System Accepted into the U.S. Food and Drug Administration’s Total Product Life Cycle (TPLC) Advisory Program Pilot